The FDA has granted clearance to an investigational new drug (IND) application of intravenous (IV) JCXH-211 in patients with advanced solid tumors.
JCXH-211 is a first-in-class, self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein.
With this IND, a phase 1/2 study will begin, and investigators will evaluate IV JCXH-211 for the treatment of malignant solid tumors.
Source : targetedonc.com/view/fda-cl...
Intravenous Vitamin C
Very promising: PIP Polyspecific Integrin-Binding Peptide, a novel and very flexible platform 
NO MORE SHOTS (SOON) Urologist won't be happy!! bye bye lupron 
Tumor growth, in mice, slowed by diet restrictions
